Controlled Delivery of Adjuvanted Multivalent Fusion Peptide Focused HIV Vaccines

About This Grant

Controlled Delivery of Adjuvanted Multivalent Fusion Peptide Focused HIV Vaccines Project Summary The development of a safe and effective vaccine against HIV-1 continues to be a global health priority and has posed a formidable scientific challenge. Recent advances in vaccinology and immunology highlight great promise in enhancing potency of vaccine-induced immunity using prolonged delivery of vaccine immunogens and adjuvants. Striking increases in the induction and persistence of germinal centers produced by such regimens in rodents and non-human primates highlight the enormous benefit in affinity maturation of vaccine-specific B cells, which is critical for HIV-1 targeted vaccines. Notably, we have recently found that the SOSIP+3M-052 combination induced antigen-specific long-lived plasma cells that successfully trafficked to the bone marrow in non-human primates (NHPs) and were found to be stable for 2-3.5 years in independent studies. We seek to capitalize on these insights with five mutually reinforcing components: (i) safe and injectable hydrogels, based on unique chemistry of tunable bond formation and disconnection, that provide uniquely tunable extended release properties; (ii) safe and highly immunogenic virus-like particle platforms for multivalent antigen display; (iii) platform-switching heterologous immunization to focus the immune response on the HIV-1 fusion peptide; (iv) state-of-the-art SOSIP-based envelope glycoprotein (Env) immunogens; and (v) a nanoparticle-based form of the TLR7/8 targeted adjuvant 3M-052. These tools will be used to generate vaccine-induced durable and protective HIV-1 specific immunity, and to study responses at the cellular, molecular, and antibody-epitope levels in NHPs to maximize the changes of clinical success. Our three specific aims blend innovative chemistry, immunogen display, and delivery (Finn lab) with optimization of vaccination strategies coupled with deep immunological and vaccinological analyses in rodents and NHPs (Kasturi Lab). Upon successful completion of the program, we will have validated a modular class of vaccine formulations and identified key determinants of vaccine-induced durable and protective humoral immunity. This work will enable rapid future optimization of candidate vaccines against HIV-1, and potentially other pathogens, to elicit broad and long-lasting protection.